Skip to main content
Atrás
ZLDPF logo

Zealand Pharma A/S

Calidad de datos: 100%
Sobreventa
ZLDPF
OTC Healthcare Biotechnology
$40.99
$0.00 (0.00%)
Cap. Mercado: 2.89B
Rango del Día
$40.99 $42.08
Rango de 52 Semanas
$35.93 $83.52
Volumen
125
Promedio 50D / 200D
$58.21 / $65.85
Cierre Anterior
$40.99

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 0.5 0.4
P/B 0.2 2.9
ROE % 55.0 3.7
Net Margin % 70.1 3.9
Rev Growth 5Y % 136.8 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 -$11.86
-$16.82 – -$5.79
 4.1 B 1
FY2029 -$31.55
-$44.76 – -$15.41
 2.5 B 1
FY2028 -$40.34
-$57.22 – -$19.70
 1.3 B 1

Puntos Clave

Revenue grew 136.77% annually over 5 years — strong growth
ROE of 55.01% indicates high profitability
Net margin of 70.05% shows strong profitability
Debt/Equity of 0.03 — conservative balance sheet
Generating 6.48B in free cash flow
P/E of 0.45 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
136.77%
Revenue (1Y)14565.56%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
55.01%
ROIC35.04%
Net Margin70.05%
Op. Margin77.66%

Seguridad

Debt / Equity
0.03
Current Ratio23.57
Interest Coverage189.81

Valoración

P/E Ratio
0.45
P/B Ratio0.20
EV/EBITDA-0.17
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 14565.56% Revenue Growth (3Y) 417.89%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 136.77% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9.19B Net Income (TTM) 6.44B
ROE 55.01% ROA 39.21%
Gross Margin 99.69% Operating Margin 77.66%
Net Margin 70.05% Free Cash Flow (TTM) 6.48B
ROIC 35.04% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.03 Current Ratio 23.57
Interest Coverage 189.81 Dividend Yield 0.00%
Valuation
P/E Ratio 0.45 P/B Ratio 0.20
P/S Ratio 0.31 PEG Ratio -0.01
EV/EBITDA -0.17 Dividend Yield 0.00%
Market Cap 2.89B Enterprise Value -1.19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9.19B 62.69M 342.79M 103.99M 292.57M
Net Income 6.44B -1.08B -703.74M -965.61M -1.02B
EPS (Diluted) 90.04 -16.24 -12.44 -20.90 -23.75
Gross Profit 9.17B 54.82M 323.61M 73.28M 173.75M
Operating Income 7.14B -1.27B -572.24M -816.60M -1.05B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16.42B 9.51B 1.98B 1.54B 2.07B
Total Liabilities 1.63B 888.86M 387.15M 723.90M 1.14B
Shareholders' Equity 14.80B 8.62B 1.59B 815.91M 927.80M
Total Debt 484.88M 391.76M 119.23M 443.47M 787.43M
Cash & Equivalents 4.57B 480.30M 449.31M 1.07B 1.13B
Current Assets 15.63B 8.53B 1.78B 1.32B 1.72B
Current Liabilities 663.46M 403.47M 284.58M 195.49M 334.32M

Puntuaciones de Estrategias

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#152 of 1024
65
Custom Capital Light Compounder
#5 of 213
81
Custom Deep Value Investing (Seth Klarman)
#283 of 820
51
Growth Price/Sales Ratio Focus (Ken Fisher)
#21 of 616
87
Custom Contrarian Investing (David Dreman)
#113 of 658
54
Value Defensive Investing (Benjamin Graham)
#460 of 708
20
Value Value Investing (Warren Buffett)
#41 of 195
52

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026
Entró Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró Capital Light Compounder
Mar 24, 2026
Entró Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026
Entró Defensive Investing (Benjamin Graham)
Mar 24, 2026
Entró Value Investing (Warren Buffett)
Mar 24, 2026